封面
市场调查报告书
商品编码
1485254

虚拟临床试验市场 - 按研究设计、类型、阶段、适应症、产业划分 - 全球预测 2024 年 - 2032 年

Virtual Clinical Trials Market - By Study Design, Type, Phases, Indication, Industry - Global Forecast 2024 - 2032

出版日期: | 出版商: Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3个工作天内

价格
简介目录

虚拟临床试验市场规模预计从 2024 年到 2032 年将以 7.1% 的复合年增长率资料。并降低了整体成本。为此,虚拟试验变得越来越受欢迎,因为它们为参与者提供了更大的可及性和便利性,从而改善了患者的招募、保留和多样性。

2023 年 10 月,Elligo Health Research 与 Avallano 合作推出了 myTrialsConnect,这是一个由人工智慧驱动的临床试验招募和参与平台,允许患者参与试验并与医疗保健提供者网路建立联繫。领先企业的类似创新将对产业成长产生正面影响。

此外,一些监管机构越来越多地支持虚拟试验方法,以提供更清晰的指导和框架。虚拟试验在促进即时资料分析和决策以提高临床研究过程的效率和速度方面的重要性日益增加,这将促进行业的成长。

虚拟临床试验市场分为研究设计、类型、阶段、适应症、产业和地区。

根据研究设计,从 2024 年到 2032 年,观测领域的市场规模将以 6.7% 的成长率资料。 。虚拟观察研究为参与者提供了更大的便利,从而提高了招募率和保留率。即时收集现实世界资料的能力也增强了研究结果的有效性和可靠性。

就产业而言,预计到 2032 年,医疗器材公司的虚拟临床试验市场将以 7.2% 的复合年增长率成长。虚拟试验减少了与传统试验相关的后勤负担,确保更快、更具成本效益的研究。对虚拟试验方法的监管支持将进一步促进该细分市场的成长。

从地区来看,从 2024 年到 2032 年,亚太地区虚拟临床试验产业将以 7.6% 的复合年增长率显着资料。对分散试验方法的需求不断增长,正在提高参与者的可及性和多样性。支持性监管框架和指南的推出正在鼓励虚拟试验方法的采用。最近,COVID-19 大流行的爆发也加速了整个亚太地区向虚拟试验的转变,以确保在面对面互动受到限制的情况下研究的连续性。

目录

第 1 章:方法与范围

第 2 章:执行摘要

第 3 章:产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 虚拟临床试验的技术进步
      • 科技在医疗保健领域的渗透率不断提高
      • 开发治疗多种疾病的新药
    • 产业陷阱与挑战
      • 严格的监管框架
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章:竞争格局

  • 介绍
  • 公司矩阵分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章:市场估计与预测:根据研究设计,2018 年 - 2032 年

  • 主要趋势
  • 介入治疗
  • 观察性
  • 扩大访问范围

第 6 章:市场估计与预测:按类型,2018 - 2032

  • 主要趋势
  • 完全虚拟试验
  • 混合虚拟试验

第 7 章:市场估计与预测:分阶段,2018 - 2032

  • 主要趋势
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第 8 章:市场估计与预测:按指标划分,2018 年 - 2032 年

  • 主要趋势
  • 中枢神经系统
  • 自体免疫/炎症
  • 心血管疾病
  • 代谢/内分泌学
  • 传染病
  • 肿瘤学
  • 泌尿生殖系统
  • 眼科
  • 其他适应症

第 9 章:市场估计与预测:按产业划分,2018 年 - 2032 年

  • 主要趋势
  • 製药和生物技术公司
  • 合约研究组织 (CRO)
  • 医疗器材企业
  • 其他行业

第 10 章:市场估计与预测:按地区,2018 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 11 章:公司简介

  • Clinical Ink
  • CROPRIME Ltd
  • ICON, plc
  • IQVIA Inc.
  • Medable, Inc.
  • Medidata
  • Oracle Corporation
  • Parexel International (MA) Corporation
  • PRA Health Sciences
  • Signant Health
简介目录
Product Code: 8438

Virtual Clinical Trials Market size is projected to expand at 7.1% CAGR from 2024 to 2032. The advancements in digital health technologies and telemedicine are enabling remote data collection, monitoring, and patient engagement while reducing the need for physical site visits and lowering overall costs. To that end, virtual trials have grown largely popular as they offer greater accessibility and convenience for participants, leading to improved patient recruitment, retention, and diversity.

In October 2023, Elligo Health Research collaborated with Avallano to introduce myTrialsConnect, an AI-driven clinical trial recruitment and engagement platform, allowing patients to participate in trials and connect with healthcare providers network. Similar innovations by leading players will positively influence the industry growth.

Additionally, several regulatory agencies are increasingly supporting virtual trial approaches for providing clearer guidance and frameworks. The growing importance of virtual trials in facilitating real-time data analysis and decision-making for enhancing the efficiency and speed of clinical research processes will add to the industry growth.

The virtual clinical trials market is segregated into study design, type, phase, indication, industry, and region.

Based on study design, the market size from the observational segment will expand at 6.7% growth rate from 2024 to 2032. Rapid advancements in digital technologies is enabling remote collection of data, making it easier to conduct observational studies without the need for physical site visits. Virtual observational studies offer greater convenience for participants, leading to improved recruitment and retention rates. The ability to collect real-world data in real-time is also enhancing the validity and reliability of study findings.

In terms of industry, the virtual clinical trials market from the medical devices companies segment is estimated to rise at 7.2% CAGR through 2032. The advancements in remote monitoring technologies is enabling medical device companies to conduct trials more efficiently. Virtual trials reduce the logistical burden associated with traditional trials, ensuring faster and more cost-effective research. The regulatory support for virtual trial methodologies will further boost the segment growth.

Regionally, the Asia Pacific virtual clinical trials industry will showcase significant growth at 7.6% CAGR from 2024 to 2032. The increasing adoption of digital health technologies is facilitating remote data collection and patient engagement in the region. The rising demand for decentralized trial approaches is improving accessibility and diversity of participants. The rollout of supportive regulatory frameworks and guidelines are encouraging the adoption of virtual trial methodologies. Lately, the onset of the COVID-19 pandemic has also accelerated the shift towards virtual trials across APAC for ensuring continuity of research amid restrictions on in-person interactions.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Technological advancements in virtual clinical trials
      • 3.2.1.2 Rising penetration of technology in healthcare
      • 3.2.1.3 Development of novel medications for various diseases
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory framework
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Study Design, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Interventional
  • 5.3 Observational
  • 5.4 Expanded access

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Fully virtual trials
  • 6.3 Hybrid virtual trials

Chapter 7 Market Estimates and Forecast, By Phases, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Phase I
  • 7.3 Phase II
  • 7.4 Phase III
  • 7.5 Phase IV

Chapter 8 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 CNS
  • 8.3 Autoimmune/inflammation
  • 8.4 Cardiovascular disease
  • 8.5 Metabolic/endocrinology
  • 8.6 Infectious disease
  • 8.7 Oncology
  • 8.8 Genitourinary
  • 8.9 Ophthalmology
  • 8.10 Other indications

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Pharmaceutical and biotechnology companies
  • 9.3 Contract research organizations (CROs)
  • 9.4 Medical devices companies
  • 9.5 Other industries

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Clinical Ink
  • 11.2 CROPRIME Ltd
  • 11.3 ICON, plc
  • 11.4 IQVIA Inc.
  • 11.5 Medable, Inc.
  • 11.6 Medidata
  • 11.7 Oracle Corporation
  • 11.8 Parexel International (MA) Corporation
  • 11.9 PRA Health Sciences
  • 11.10 Signant Health